3934-86-9

Basic information

• Product Name: 3,4-DIHYDROXY-5-METHOXYBENZOIC ACID METHYL ESTER
• Synonyms: RARECHEM AL BF 0702;3,4-DIHYDROXY-5-METHOXYBENZOIC ACID METHYL ESTER;METHYL 3,4-DIHYDROXY-5-METHOXYBENZOATE;M3OMG;Benzoic acid, 3,4-dihydroxy-5-Methoxy-, Methyl ester;Methyl 3-methoxy-4,5-dihydroxybenzoate
• CAS NO: 3934-86-9
• Molecular Formula: C₉H₁₀O₅
• Molecular Weight: 198.17
• Mol File: 3934-86-9.mol
• Article Data: 27

Chemical Properties

• Boiling Point: 391.7 °C at 760 mmHg
• Flash Point: 160.5 °C
• Appearance: /
• Density: 1.337 g/cm³
• Vapor Pressure: 1.07E-06mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 3,4-DIHYDROXY-5-METHOXYBENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-DIHYDROXY-5-METHOXYBENZOIC ACID METHYL ESTER(3934-86-9)
• EPA Substance Registry System: 3,4-DIHYDROXY-5-METHOXYBENZOIC ACID METHYL ESTER(3934-86-9)

Safety Data

• Hazardous Substances Data: 3934-86-9(Hazardous Substances Data)

Usage

General Description

3,4-Dihydroxy-5-methoxybenzoic acid methyl ester is a chemical compound with the molecular formula C10H10O6 and molecular weight of 226.18 g/mol. This ester compound belongs to the class of organic compounds known as dimethoxybenzenes, characterized by a phenyl group that carries two methoxy groups. It is primarily recognized due to its potential biological activities and is used in various synthetic procedures. However, it's not typically found naturally occurring and is usually created in a lab setting for specific usage. While its overall toxicity and interaction with human physiology remain largely unresearched, like other chemicals, it should be handled with appropriate safety measures.

InChI:InChI=1/C9H10O5/c1-13-7-4-5(9(12)14-2)3-6(10)8(7)11/h3-4,10-11H,1-2H3

Upstream product

• 99-24-1 methyl galloate 
• 74-88-4 methyl iodide 
• 40918-90-9 3'-Hydroxymethyleugenol 
• 169229-45-2 methyl 3-methoxy-1,2-dioxocyclohexa-3,5-diene-5-carboxylate 
• 408340-58-9 7-hydroxy-2-oxo-benzo[1,3]dioxole-5-carboxylic acid 
• 77-78-1 dimethyl sulfate 
• 67-71-0 dimethylsulfone 
• 67-56-1 methanol 
• 1000180-43-7 2-(3,4-dihydroxy-5-methoxyphenyl)-2-methoxyacetonitrile 
• 69829-46-5 methyl 7-hydroxy-2,2-diphenylbenzo[d]-1,3-dioxole-5-carboxylate 
• 149-91-7 3,4,5-trihydroxybenzoic acid 
• 526221-05-6 2-ethoxy-7-hydroxy-benzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 102706-14-9 methyl 3-methoxy-4,5-diphenylmethylenedioxybenzoate 
• 3934-84-7 3,4-dihydroxy-5-methoxybenzoic acid 

Downstream Products

• 81474-46-6 4-bromo-7-methoxybenzo[1,3]dioxole-5-carboxylic acid methyl ester 
• 111897-19-9 DDB 
• 22934-58-3 methyl 7-methoxybenzo[d][1,3]dioxole-5-carboxylate 
• 526-34-1 5-methoxy-3,4-methylenedioxybenzoic acid 

Relevant articles and documents

Asymmetric total synthesis of four bioactive lignans using donor-acceptor cyclopropanes and bioassay of (?)- and (+)-niranthin against hepatitis B and influenza viruses

The asymmetric total synthesis of four lignans, dimethylmatairesinol, matairesinol, (?)-niranthin, and (+)-niranthin has been achieved using reductive ring-opening of cyclopropanes. Moreover, we performed bioassays of the synthesized (+)- and (?)-niranthins using hepatitis B and influenza viruses, which revealed the relationship between the enantiomeric structure and the anti-viral activity of niranthin.

Synthesis method of 2-bromo-3, 4-methylenedioxy-5-methoxybenzoic acid methyl ester

The invention belongs to the field of chemical pharmacy, and specifically discloses a preparation method of 2-bromo-3, 4-methylenedioxy-5-methoxybenzoic acid methyl ester. The preparation method comprises the following steps: by taking gallic acid as a ra

Design and synthesis of novel parabanic acid derivatives as anticonvulsants

In this work a set of novel derivatives of parabanic acid 9a-d, 12a-d and 13a-d was synthesized and their anticonvulsant potential was evaluated. All the compounds under investigation exhibited anticonvulsant activity in both scPTZ and MES tests. In phase II anticonvulsant study, the trimethoxy phenyl derivative 9a evoked the highest potency among the tested compounds in scPTZ test. It displayed 1.72- and 17.05-folds activity more than the standard drugs phenobarbital and ethosuximide, respectively. In addition, the margin of safety for compound 9a is better than that of the reference antiepileptic drug ethosuximide. Also, compound 9a was devoid of hepatotoxicity indicated by measurements of serum level of ALT, AST, ALP, albumin and total protein. Furthermore, treatment with compound 9a significantly increased the GABA brain level by 2.56-folds compared to the control value. Additionally, molecular docking was performed on the active site of GABA-AT to clarify the interactions of the most potent compound 9a with the enzyme. In MES test, compound 12a exhibited the most potent activity against electric stimuli-induced seizures with the lowest ED50 = 13.7 mg/kg and protective index >36.5. Both candidates 9a and 12a could be a good starting point to develop new molecules as novel antiepileptic drugs.